IL23A and colitis: This might explain the opposing effects observed in clinical trial in active crohn’s disease where IL-17A inhibition resulted in worsening of colitis, but treatment with anti-IL-12/IL-23p40 as well as p19 inhibition (78) improved inflammation (79).